Last updated on July 2019

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)


Brief description of study

HPV-303 is a prospective, randomized, double-blind, placebo-controlled phase 3 study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA 5PSP in adult women with histologically confirmed high-grade squamous intraepithelial lesions (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) of the cervix, associated with HPV-16 and/or HPV-18.

Clinical Study Identifier: NCT03721978

Find a site near you

Start Over

Magnolia Ob/Gyn Research Center, LLC

Myrtle Beach, SC United States
6.75miles
  Connect »

Venus Gynecology, LLC

Myrtle Beach, SC United States
6.75miles
  Connect »